CAS: 2363-59-9; Boldenone 17-Acetate

上下游产品

CAS号1045-69-8 醋酸睾酮 | CAS号58-22-0 睾酮 | CAS号82926-51-0 17β-acetoxy-2β,... | CAS号1164-92-7 Androstan-3-one... | CAS号15359-18-9 17β-Acetoxy-3-o... | CAS号108-24-7 乙酸酐 | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号108-75-8 2,4,6-三甲基吡啶 | CAS号1045-69-8 醋酸睾酮

📜醋酸睾酮置于thallium(III) Acetate体系中,用 溶剂黄146 用作溶剂,化学反应生成17-乙酸勃地酮
参考文献:Romeo,A.; Ortar,G.,Tetrahedron,1972,Vol. 28,P. 5338-5339
标题:Romeo,A.; Ortar,G.,Tetrahedron,1972,Vol. 28,P. 5338-5339

专利信息

专利号:US-5908944-A
优先权日:1991-09-27
标题 :Methylation or ethylation agent and process for 1,4-addition of a methyl or ethyl group to an α, β-unsaturated keto compound
发明人：WESTERMANN JUERGEN; NICKISCH KLAUS
权利人:SCHERING AG
摘要:This invention describes a new methylation or ethylation agent containing trimethyl aluminum or dimethyl zinc or triethyl aluminum as methyl or ethyl source, which additionally contains catalytic amounts of one or more copper(I) and/or copper(II) compounds as well as a process for the 1,4-addition of a methyl or ethyl group to an α,β-unsaturated or an α,β-double unsaturated ketone or an α,β-unsaturated aldehyde using the agent according to the invention. n By using only catalytic amounts of copper and a CKW (chlorinatedhydrocarbon)-free reaction medium, the new methylation/ethylation agent/process is distinguished by its environmental compatibility and it is, for example, suitable for the production of initial products for the synthesis of biologically effective compounds.

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.